Comparison

Recombinant Human PD-L1/B7-H1/CD274 Protein (His Tag)(Active)

Item no. ELS-PKSH031886-100ug
Manufacturer Elabscience
Amount 100 ug
Quantity options 100 ug 200 ug
Category
Type Proteins
Format Lyophilized Powder
Specific against Human (Homo sapiens)
Host HEK293 cells
Conjugate/Tag HIS
Purity > 98 % as determined by reducing SDS-PAGE.
Sequence Met 1-Thr 239
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias Programmed Cell Death 1 Ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1, CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1
Similar products CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1, B7 homolog 1, PD-L1, B7-H1, PDCD1 ligand 1, Programmed death ligand 1, Programmed Cell Death 1 Ligand 1
Shipping condition Cool pack
Available
Manufacturer - Conjugate / Tag
C-His
Shipping Temperature
This product is provided as lyophilized powder which is shipped with ice packs.
Storage Conditions
Lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8C for 2-7 days. Aliquots of reconstituted samples are stable at < -20C for 3 months.
Calculated Molecular Weight
35-38 kDa
Observed Molecular Weight
26.8 kDa
Background
Programmed death-1 ligand-1 (PD-L1; CD274; B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain; and together with PD-L2; are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells; PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly; it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.Immune CheckpointImmune Checkpoint Blockade: Blocking Antibodies      Immune Checkpoint Blockade: PD-L1 / B7-H1 / CD274 Blocking AntibodiesImmune Checkpoint Detection: Antibodies      Immune Checkpoint Detection: ELISA Antibodies      Immune Checkpoint Detection: IHC Antibodies      Immune Checkpoint Detection: ICC Antibodies      Immune Checkpoint Detection: FCM Antibodies      Immune Checkpoint Detection: WB AntibodiesImmune Checkpoint Proteins      PD-L1 / B7-H1 / CD274 Immune Checkpoint ProteinsImmune Checkpoint Targets      Co-inhibitory Immune Checkpoint Targets Immunotherapy      Cancer Immunotherapy      Targeted Therapy
Endotoxin
< 1.0 EU per ug as determined by the LAL method.
Reconstitution
Please refer to the printed manual for detailed information.
Formulation
Lyophilized from sterile PBS; pH 7.4
Activity
Measured by its binding ability in a functional ELISA. Immobilized human B7-H1 at 20 ug/ml (100 ul/well) can bind human PD1 with a linear ranger of 0.032-0.8 ug/ml.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close